Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Cambridge BioMarketing Introduces RareID to Uncover Rare Disease Solutions

May 14, 2019 GMT

BOSTON--(BUSINESS WIRE)--May 14, 2019--

Cambridge BioMarketing, an Ashfield company, part of UDG Healthcare plc and the world’s leading rare disease agency, today announced the launch of RareID, the agency’s new, proprietary approach to identifying rare disease market solutions.

RareID uses proven, predictive model-matching applications and journey-mapping techniques customized for the rare disease market, enabling clients to confidently understand how to best reach their customers. By combining client algorithms with Cambridge BioMarketing’s rare disease knowledge base, the solution helps develop the most effective market-shaping strategies, messaging, and patient-find-and-activate initiatives to help clients reach patients efficiently and effectively.


“Each rare disease patient and their respective community is even more dynamic and rare than their diagnosis,” said Marissa McNally, head of Strategy, Cambridge BioMarketing. “RareID enables us to help our clients understand those patients at deeper levels and deliver their solutions directly to those who need them most.”

The development of RareID stems from the agency’s enduring commitment to service, strategy, and a deep understanding of rare medicine’s intersection with omnichannel solutions. Four tenets of the approach include:

  • Find both diagnosed and undiagnosed patients—and the HCPs likely to treat them—so that they can get the answers, medicine, and support they deserve quicker than ever before.
  • Develop markets and launch meaningful brands—for both novel and crowded treatment categories—that accelerate time to diagnosis, empower patients to demand more from their HCPs, and give HCPs a concrete way to offer hope to some of their toughest cases.
  • Activate rare communities to drive awareness, diagnosis, and urgency, and spark patients and HCPs to champion new treatment paradigms that align with their wants and needs.
  • Nurture relationships between patients, HCPs, industry, and advocacy organizations to foster a level of empathy and understanding that results in optimal support for rare communities.

RareID marks the latest chapter in the agency’s evolution including a new, interactive website, as well as an updated color palate, evolving from Cambridge BioMarketing’s original black and red branding to navy and a brighter red. The brand updates reflect the agency’s roots in the rare experience and represent its sophistication and deep knowledge in rare disease marketing.

About Cambridge BioMarketing

Founded in 2001, Cambridge BioMarketing is a U.S.-based communications agency specializing in rare orphan diseases with over 100 employees. Headquartered in Boston, MA with offices in Oakland, CA, Cambridge BioMarketing is an industry leader in orphan drug launches, advising pharmaceutical companies with an integrated focus on both traditional healthcare professional (HCP) programs and direct-to-patient work. In partnering with predominantly pharmaceutical and biotech customers, the agency’s goal is to bring physicians, specialists, and patient communities together on behalf of clients to transform human health in the face of devastating, under-appreciated disease states. Cambridge BioMarketing’s primary service offerings include: launch readiness support; digital strategy; market analytics; integrated marketing; patient identification and acquisition; medical affairs support; line extensions and patient retention and adherence programs.


For more information, please go to:  http://cambridgebmg.com/

About Ashfield:

Ashfield is part of UDG Healthcare plc, a global leader in commercialization services for the healthcare industry. We partner with our clients across Advisory, Healthcare Communications, Commercial, Patient Solutions and Medical Affairs to build creative, scalable and tailored health solutions that are executed flawlessly, to deliver positive outcomes for patients and add value to your business. With 7,000 employees, the company operates in 25 countries, delivering services in more than 50 countries across Europe, North America, South America and Asia. It works with more than 250 businesses, including all of the world’s top 25 pharmaceutical companies.

Its mission is to partner with its clients, helping to improve lives by ensuring healthcare professionals and patients get the medicines, knowledge and support they need.

Ashfield provides contract sales teams, customer service reps, medical science liaison officers, remote detailing, nurse educators, medical information, healthcare communications, market access, market research, training, live and virtual events, digital, creative, pharmacovigilance, audit and advisory services.

For more information, go to  www.ashfieldhealthcare.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190514005189/en/

CONTACT: PAN Communications, for Cambridge BioMarketing

Taylor VerMeer, 617-502-4300




SOURCE: Cambridge BioMarketing

Copyright Business Wire 2019.

PUB: 05/14/2019 09:00 AM/DISC: 05/14/2019 09:01 AM